Erratum: A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial (Ann Surg. (2023) 277 (689-696) DOI: 10.1097/SLA.0000000000005415)

In the April 2023 issue of Annals of Surgery, a few corrections are needed in the article by Schut et al1, "A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial."The sentences "One patient was excluded from the analyses because her DTF was retrospectively considered as a residual tumor, progressing after prior surgical resection. Ultimately, 105 patients were analyzed until their last followup. Baseline characteristics are depicted in Table 1"and "Twenty-one patients with PD switched to some form of active treatment. These patients had larger tumors compared to patients who continued AS (P = 0.013; Table 3). In 13 of the 21 progressive patients who continued AS, a decrease in tumor size was observed after initial PD. Time between start PD and start decrease in tumor size varied between 5.8 to 32.7 months. In 4 of the 21 patients the DTF tumor remained stable after PD; in 3 patients there was ongoing PD and 1 patient was lost to follow-up (Fig. 3A)."were erroneously removed from the Results section. The Production team apologize for these errors.